|
HAIFA, Israel--(BUSINESS WIRE)--Oct. 26, 2005--In BW5163 issued Oct.
26, 2005: Please replace the release with the following corrected
version due to multiple revisions.
The corrected release reads:
PLURISTEM APPOINTS DR. ORA ADOUT-BURGER VICE PRESIDENT OF DEVELOPMENT
Distinguished Scholar to Implement Development Strategies to Meet
Corporate Business Objectives, Advance the Company's Core Technology to
Clinical Trials and Further the Company's Integrated Research Programs
with Technion and Biological Industries Ltd.
Pluristem Life Systems (OTC BB:PLRS - News), a biotechnology company
dedicated to the expansion of stem cells from umbilical cord blood to
address a myriad of fatal illnesses, today announced that Dr. Ora
Adout-Burger was appointed Vice President of Development.
Dr. Burger possesses recent and extensive experience in the management
of multidisciplinary and multifaceted research and development programs
and is highly experienced in the preparation and delivery of science and
technology-related programs.
Dr. Burger was recruited to Pluristem in 2003 to promote the research of
hemapoietic stem cells (HSC) growing and expanding in a physiological
like microenvironment 3-D culture in the Company' novel PluriX(TM)
bioreactor. She was subsequently promoted to manage turnkey projects in
Research and Development - specifically the expansion of transplantable
HSC using a 3-D biodegradable scaffolding platform in the PluriX(TM)
bioreactor. This project is co-sponsored by the Chief Scientist of the
Israeli Ministry of Industry and Trade under the most prestigious
"Magneton" grant program directed toward facilitating technology
transfer to the forefront of innovation from the University to leading
high-technology and biotechnology companies.
Prior to joining Pluristem, Dr. Burger served as a Research and
Development Advisor in several emerging-growth biotechnology companies
validating technologies for further development. She acted as Director
of Research and Development for Diagnostic Technology where she led the
development of ELISA kit, intended for the prenatal diagnose of
pregnancy complications such as preeclampsia, preterm delivery and fetal
growth restriction.
Dr. Burger was responsible for the entire development cycle from the
academic bench, into the clinical research, controlling the process of
manufacturing, development of the laboratory kit which was transformed
to an industrial kit, preparation of product development files meeting
SOP standards, preparation of characterization files and instruction for
use, preparation of manufacturing files meeting ISO9001 standards, and
development of reporting processes and data processing of clinical test
results, to regulatory approval and the award of the European Union CE
Mark.
Dr. Burger holds a B.A. and MSc. in plant science from the faculty of
agronomy of the Hebrew University and a DSc. in Biotechnology
Engineering from Technion. She completed postdoctoral training at
Technion and Tel Aviv University, Sackler School of Medicine, working on
therapeutic models to cure the damage of Helicobacter pylori, a
bacterial infection which causes ulcers, gastritis, and gastric cancer.
Her work was recently re-illuminated following the 2005 Nobel Prize in
Medicine to the scientists who discovered the clinical central
importance of the subject: Ulcer Derived from Bacterial Infections. Dr.
Burger was until recently a lecturer in Biotechnology and Food
Engineering Faculty at the Technion institute.
"We appointed Dr. Burger thoroughly confident that her experience and
expertise will bring Pluristem's product development activities to the
next level, critical to our success," stated Zami Aberman, CEO.
As we continue movement towards human clinical trails and to consummate
strategic alliances and joint ventures that further the capabilities of
the U.S. patented-PluriX(TM) bioreactor, Dr. Burger's keen ability to
bring projects from conception to fruition will prove extremely
valuable," Aberman concluded.
About Pluristem
Pluristem is a biopharmaceutical company developing stem cell products
for cell regenerative therapy. Pluristem's platform for expanding stem
cells offers newly developing technology and multiple product
opportunities in many therapeutic areas. Pluristem has exclusive rights
to the Plurix(TM) cell expansion system under a licensing agreement with
Technion Institute of Technology and the Weisman Institute of Science.
For more information, visit the Company's website at: www.pluristem.com.
Safe Harbor Statement
This press release contains statements, which may constitute
"forward-looking statements". Those statements include statements
regarding the intent, belief or current expectations of Pluristem Life
Systems, Inc., and members of our management as well as the assumptions
on which such statements are based. Forward-looking statements in this
release include statements that include that Dr. -Burger will Implement
Development Strategies to Meet our Corporate Business Objectives,
Advance the Company's Core Technology to Clinical Trials and Further the
Company's Integrated Research Programs; and that our technology offers
opportunities for therapeutic products and to save lives. Factors which
may significantly change or prevent our forward looking statements from
fruition include that we may be unsuccessful in developing any products;
potential successful challenges to our patent by competitors; that our
patents are not sufficient to protect essential aspects of our
technology; that competitors may invent better technology; that we may
not have sufficient financing to develop our products; our products may
not work as well as hoped or worse, they may harm recipients; that key
employees may not remain with our company; and that we may not be able
raise funding for development or working capital when we require it. As
well, our products may never develop into useful products and even if
they do, they may not be approved for sale to the public. For further
risk factors see the Company's latest 10-KSB filed with the SEC.
--------------------------------------------------------------------------------
Contact:
For Pluristem Life Systems, Inc.
DeMonte Associates
Cynthia DeMonte, 212-605-0525
cdemonte@aol.com
--------------------------------------------------------------------------------
Source: Pluristem Life Systems, Inc.
|
